Company Overview and News

0
Skeena Sells Porter Idaho Silver Project

2018-07-16 accesswire
VANCOUVER, BC / ACCESSWIRE / July 16, 2018 / Skeena Resources Limited (TSX.V: SKE, OTCQX: SKREF) ("Skeena" or the "Company") is pleased to announce that it has entered into a purchase and sale agreement (the "Agreement") to sell Mount Rainey Silver Inc. ("Mount Rainey") to StrikePoint Gold Inc. ("StrikePoint"). Mount Rainey holds the Company's 100% interest in the Porter Idaho property (the "Property") located near Stewart, British Columbia.
SKE STKXF SKRED SKP SKREF

0
Skeena Intersects 16.02 g/t Gold Over 12.25 Metres at Snip

2018-07-11 accesswire
VANCOUVER, BC / ACCESSWIRE / July 11, 2018 / Skeena Resources Limited (TSX-V: SKE; OTCQX: SKREF) ("Skeena" or the "Company") is pleased to report additional assay results from the Phase II underground drilling program at the Company's 100% owned Snip Gold Project ("Snip") located in the Golden Triangle of British Columbia.
SKE SKRED SKREF

0
Skeena Intersects 9.14 g/t Au Over 10.2 Meters at Snip

2018-06-26 accesswire
VANCOUVER, BC / ACCESSWIRE / June 26, 2018 / Skeena Resources Limited (TSX.V: SKE, OTCQX: SKREF) ("Skeena" or the "Company") is pleased to announce additional assays from 11 holes of the Phase II underground drilling program at the Company's 100% owned Snip Gold Project ("Snip") located in the Golden Triangle of British Columbia.
SKE SKRED SKREF

0
Skeena Drilling Intersects More High-grade Gold at Snip

2018-05-16 accesswire
- 14.49 g/t Au over 4.1 m in the Twin Zone Extension - 11.74 g/t Au over 4.5 m in the 412 Zone Infill
SKE SKRED SKREF

0
Skeena To Sell Porter Idaho Silver Property

2018-05-02 accesswire
VANCOUVER, BC / ACCESSWIRE / May 2, 2018 / Skeena Resources Limited (TSX-V: SKE, OTCQX: SKREF) ("Skeena" or the "Company") has entered into a non-binding letter of intent with StrikePoint Gold Inc. (SKP) to sell the Porter Idaho Silver Property ("Porter Idaho" or the "Property") near Stewart, British Columbia (the "Transaction") for a combination of cash and common shares.
SKE STKXF SKRED SKP SKREF

0
Skeena Initiates Phase II Underground Drilling at Snip

2018-04-03 globenewswire
VANCOUVER, B.C., April 03, 2018 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX.V:SKE) (OTCQX:SKREF) (“Skeena” or the “Company”) is pleased to announce the commencement of underground drilling at its 100% owned Snip Project located in the Golden Triangle of British Columbia. The budgeted Phase II drill program totalling 11,000 metres is being performed from the existing underground infrastructure utilizing two drill rigs.
SKE SKRED SKREF

0
Skeena Closes Oversubscribed Private Placement

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX.V:SKE) (“Skeena” or the “Company”) is pleased to announce that it has closed its previously announced private placement of units (the “Units”) and flow-through common shares (the “FT Shares”) of the Company (the “Offering”) pursuant to an agency agreement dated March 29, 2018 (the “Agency Agreement”) between the Company and PI Financial Corp.
SKE SKRED SKREF

0
Skeena Financing Oversubscribed and Upsized

2018-03-19 globenewswire
VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX.V:SKE) (OTCQX:SKREF) (“Skeena” or the “Company”) is pleased to announce that the best efforts private placement financing previously announced on March 13, 2018 (the “Offering”) is now oversubscribed and as a result the Company has upsized the Offering. The Offering will now consist of the sale of approximately 9,139,451 units (the “Units”) and approximately 4,223,572 flow-through common shares (the “FT Shares”) of the Company to raise aggregate gross proceeds of approximately C$8.
SKE SKRED SKREF

0
BRIEF-Skeena Announces $6.0 Million Private Placement Financing

2018-03-13 reuters
* SKEENA RESOURCES - PRIVATE PLACEMENT OF UP TO 5 MILLION UNITS AND UP TO 4.3 MILLION FLOW-THROUGH SHARES OF CO
SKE SKRED SKREF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...